There is no perfect way to produce fibrin, a protein essential to blood clotting. Making a transgenic version of the compound raises concerns over the transfer of animal viruses to humans, while cell culture methods in which fibrin is isolated from human plasma give low levels of fibrin expression and carry the risk of transferring an infectious disease such as hepatitis.

VITX's fibrin sealant tissue